What a second booster dose of mRNA COVID-19 vaccines tells us

What a second booster dose of mRNA COVID-19 vaccines tells us

Real-world studies have shown waning vaccine effectiveness against both SARS-CoV-2 infection and COVID-19-related hospitalisation within 2·5 months after a first booster dose of COVID-19 mRNA vaccine, especially for the SARS-CoV-2 omicron (B.1.1.529) variant.1 Several countries have thus recommended...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2022-08, Vol.22 (8), p.1092-1093
Hauptverfasser: Loubet, Paul, Launay, Odile
Format: Artikel
Sprache:eng
Schlagworte:
Age
Age groups
Comment
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Hospitalization
Humans
Immunization Schedule
Immunization, Secondary
Immunoglobulin G
Infectious diseases
Lymphocytes T
mRNA
mRNA vaccines
Proteins
RNA, Messenger
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccine efficacy
Vaccines
Vaccines, Synthetic
Viral diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Real-world studies have shown waning vaccine effectiveness against both SARS-CoV-2 infection and COVID-19-related hospitalisation within 2·5 months after a first booster dose of COVID-19 mRNA vaccine, especially for the SARS-CoV-2 omicron (B.1.1.529) variant.1 Several countries have thus recommended a second booster dose of COVID-19 mRNA vaccine (ie, a fourth vaccine dose) in older and immunocompromised individuals at higher risk for severe disease, hospitalisation, and death. [...]humoral responses increased to similar levels in the older (≥70 years) versus younger (
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(22)00282-1